Repurposing Bromocriptine for Abeta Metabolism in Alzheimer's Disease

Inclusion Criteria: * Alzheimer's disease patients with PSEN1 mutations * Patients diagnosed with "probable AD" according to the diagnostic guideline of NIA-AA or "probable Alzheimer-type dementia" according to the diagnostic criteria for Alzheimer's disease specified in DSM-5 * An MMSE-J score of \<= 25 * Patients whose cognitive function and everyday function are obviously impaired based on their medical record or information provided by a person who knows the patient well * Patients for whom intellectual disability and mental disorders other than dementia can be ruled out based on their academic background, work history, and life history. * Patients with a reliable and close relationship with a partner/caregiver * Age\>=20 years at the time of giving informed consent * Written informed consent has been obtained from the patient or his/her legally acceptable representative to participate in this trial Exclusion Criteria: * Difficulty with the oral intake of tablets * Patients receiving anti-dementia drugs who have changed the dosing regimen during the 2 months prior to giving informed consent * Patients with dementia due to pathology other than Alzheimer's disease (e.g., vascular dementia, frontotemporal dementia, Lewy body dementia, progressive supranuclear palsy, corticobasal degeneration, Huntington's disease, and prion disease) * Presence of clinically relevant or unstable mental disorders. Patients with major depression in remission can be enrolled. * Imminent risk of self-harm or harm to others * Body mass index (BMI) of \<= 17 or \>= 35 * Patients with a history of alcohol dependence, drug dependence, or drug abuse within the 5 years before providing informed consent * HBs antigen positive * Anti-HIV antibody positive * Anti-HTLV-1 antibody positive * Patients with an active infection, such as hepatitis C and syphilis (STS/TPHA) * Patients with the following liver function values on the test before enrollment * AST(GOT) \> 4.0 x Upper limit of the institutional reference range or * ALT (GPT) \> 4.0 x Upper limit of the institutional reference range * Patients who have uncontrolled, clinically significant medical conditions (e.g., diabetes melitus, hypertension, thyroid/endocrine disease, congestive cardiac failure, angina pectoris, cardiac/gastrointestinal disease, dialysis, and abnormal renal function with an estimated CLcr \< 30 mL/min)within 3 months prior to giving informed consent in addition to the underlying disease to be investigated in the trial and for whom the investigator or sub-investigator considers that there is a significant medical risk in the patient's participation in the trial * Patients with long QT syndrome or tendency toward prolonged QTc interval (male: \>=470 msec, female: \>= 480 msec), or patients with a history/complication of torsades de pointes * Patients with a history of malignancies within 5 years prior to providing informed consent. However, patients with the following diseases can be enrolled if they are treated appropriately: * Skin cancer (basal cell, squamous cell) * Cervical carcinoma in situ * Localized prostate cancer * Malignancies that have not recurred for at least 3 years since surgery and the patient's physician has determined that the risk of recurrence is low * Patients with clinically significant vitamin B1/B12 deficiency or folic acid deficiency within 6 months prior to giving informed consent * Patients who have participated in other clinical research/trials involving interventions within the 3 months prior to providing informed consent * Patients who have previously received bromocriptine or TW-012R * Patients with a history of hypersensitivity to bromocriptine or ergot alkaloids * Patients with current or a history of thickened heart valve cusps, restricted heart valve motion, and the associated heart valve lesions, such as stenosis, confirmed by echocardiography * Pregnant females, lactating females, females who may be pregnant, and females who wish to become pregnant * Other patients who are considered inappropriate to participate in this trial at the discretion of the investigator or sub-investigator